Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

@article{Kostenuik2009DenosumabAF,
  title={Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.},
  author={Paul J. Kostenuik and Hung Q. Nguyen and James McCabe and Kelly S Warmington and Carol Kurahara and Ning Sun and Ching Shiang Chen and Luke Li and Russ C Cattley and Gwyneth Van and Shelia Scully and Robin L. Elliott and Mario Grisanti and Sean E Morony and Hong Lin Tan and Frank J Asuncion and Xiaodong Li and Michael Stuart Ominsky and Marina Stolina and Denise Dwyer and William C. Dougall and Nessa Hawkins and William J. Boyle and William S Simonet and John K. Sullivan},
  journal={Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research},
  year={2009},
  volume={24 2},
  pages={182-95}
}
RANKL is a TNF family member that mediates osteoclast formation, activation, and survival by activating RANK. The proresorptive effects of RANKL are prevented by binding to its soluble inhibitor osteoprotegerin (OPG). Recombinant human OPG-Fc recognizes RANKL from multiple species and reduced bone resorption and increased bone volume, density, and strength in a number of rodent models of bone disease. The clinical development of OPG-Fc was discontinued in favor of denosumab, a fully human… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS